NFKB1 and diffuse large B-cell lymphoma: In this study, the hypothesis that the addition of ibrutinib and lenalidomide would inhibit BCR signaling and NF-κB in ABC DLBCL and thereby enhance sensitivity to DA-EPOCH-R was assessed.